24,514 results match your criteria Thyroid Papillary Carcinoma


Cancer stem cell-like cells-derived exosomal CDKN2B-AS1 stabilizes CDKN2B to promote the growth and metastasis of thyroid cancer via TGF-β1/Smad2/3 signaling.

Exp Cell Res 2022 Jun 21:113268. Epub 2022 Jun 21.

Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China.

As CDKN2B-AS1 is demonstrated to exert promotive effects on thyroid cancer (TC), this research aims to investigate the role of cancer stem cell-like cells (CSCs)-derived exosomal CDKN2B-AS1 in TC and the underlying regulatory mechanism. Specifically, CDKN2B expression and the correlation of CDKN2B with CDKN2B-AS1 in TC were determined via bioinformatics analysis and further verified by qRT-PCR. After transfection or co-culture with CSCs-derived exosomes, viability, migration, and invasion of TPC-1 and SW579 cells were evaluated by CCK-8, wound healing, and transwell assays, respectively. Read More

View Article and Full-Text PDF

BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers.

J Cell Mol Med 2022 Jun 24. Epub 2022 Jun 24.

Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.

BRAF T1799A mutation is the most common genetic variation in thyroid cancer, resulting in the production of BRAF V600E mutant protein reported to make cells resistant to apoptosis. However, the mechanism by which BRAF V600E regulates cell death remains unknown. We constructed BRAF V600E overexpression and knockdown 8505C and BCPAP papillary and anaplastic thyroid cancer cell to investigate regulatory mechanism of BRAF V600E in cell death induced by staurosporine (STS). Read More

View Article and Full-Text PDF

SURVIVIN POSITIVITY AND PROGNOSTIC FACTORS IN PAPILLARY THYROID CARCINOMAS.

Acta Endocrinol (Buchar) 2021 Oct-Dec;17(4):455-461

Dept. of Pathology, Trakya University, Faculty of Medicine, Ankara, Turkey.

Context: Papillary thyroid carcinoma(PTC)s are the indolent progressive tumours. Survivin is a unique bifunctional protein with cell cycle regulation and apoptosis inhibition. The expression of this protein has been shown to be increased in thyroid tumours correlated with aggressive behavior from well differentiated to anaplastic. Read More

View Article and Full-Text PDF

Genetic Panel Test of Double Cancer of Signet-Ring Cell/Histiocytoid Carcinoma of the Eyelid and Papillary Thyroid Carcinoma: Case Report and Literature Review.

Cureus 2022 May 21;14(5):e25192. Epub 2022 May 21.

Otolaryngology, Gifu University Graduate School of Medicine, Gifu, JPN.

Signet-ring cell/histiocytoid carcinoma (SRCHC) is a rare, aggressive neoplasm that often originates in the eyelid. We present a rare case of a 64-year-old male with SRCHC and papillary thyroid carcinoma (PTC) that underwent exome panel sequencing with next-generation sequencing (NGS). In addition, we reviewed reports of genetic mutations in SRCHC and compared them with our results. Read More

View Article and Full-Text PDF

The Emerging Role of EVA1A in Different Types of Cancers.

Int J Mol Sci 2022 Jun 15;23(12). Epub 2022 Jun 15.

School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.

Eva-1 homolog A (EVA1A), also known as transmembrane protein 166 (TMEM166) and regulator of programmed cell death, is an endoplasmic reticulum associated protein, which can play an important role in many diseases, including a variety of cancers, by regulating autophagy/apoptosis. However, the related mechanism, especially the role of EVA1A in cancers, has not been fully understood. In this review, we summarize the recent studies on the role of EVA1A in different types of cancers, including breast cancer, papillary thyroid cancer, non-small cell lung cancer, hepatocellular carcinoma, glioblastoma and pancreatic cancer, and analyze the relevant mechanisms to provide a theoretical basis for future related research. Read More

View Article and Full-Text PDF

Sarcoidosis Mimicking Primary Lung Cancer on Tc-3PRGD2 Scintigraphy in a PTC Patient.

Diagnostics (Basel) 2022 Jun 8;12(6). Epub 2022 Jun 8.

Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.

Sarcoidosis is a multi-system disease of unknown etiology that typically occurs in middle-aged adults, often presenting as the formation of granulomas in various organs, including the lungs. Non-typical pulmonary sarcoidosis is rare, and it isnecessary to distinguish its imaging features from lung cancer and tuberculosis. They may appear as an irregular mass with multiple nodules on thoracic computed tomography (CT). Read More

View Article and Full-Text PDF

Malignant Clinical Course of "Proliferative" Ovarian Struma: Diagnostic Challenges and Treatment Pitfalls.

Diagnostics (Basel) 2022 Jun 7;12(6). Epub 2022 Jun 7.

Pathology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Struma ovarii (SO) is a monodermal teratoma predominantly composed of thyroid tissue (TT) showing benign, "proliferative", or malignant histology. By imaging, a 38-year-old patient with lower backache revealed a 6.2-cm vertebral lesion (L5). Read More

View Article and Full-Text PDF

Diagnostic Significance of FNAB miRNA Expression in Papillary Thyroid Carcinoma.

Diagnostics (Basel) 2022 Jun 3;12(6). Epub 2022 Jun 3.

Department of Radiology, Nuclear Medicine and Medical Physis, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Santariskiu 2, 08661 Vilnius, Lithuania.

The aim of the study was to evaluate the diagnostic utility of specific miRNAs in the preoperative assessment of thyroid nodules. One hundred and sixty thyroid fine needle aspiration biopsy (FNAB) samples with suspected thyroid carcinoma were collected. To detect the levels of miRNA expression in FNAB, next generation small RNA sequencing was performed in 60 samples. Read More

View Article and Full-Text PDF

Advances in Thyroid Carcinoma.

Authors:
Iñigo Landa

Cancers (Basel) 2022 Jun 13;14(12). Epub 2022 Jun 13.

Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, MA 02115, USA.

"Thyroid cancer" encompasses a heterogeneous group of tumors that range from the predominant papillary thyroid cancer (PTC) subtype, which shows excellent survival rates, to the poorly differentiated (PDTC) and anaplastic thyroid cancer (ATC) forms, accounting for most of the disease-related morbidity and mortality [... Read More

View Article and Full-Text PDF

Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.

In Vivo 2022 Jul-Aug;36(4):1551-1569

Department of General and Endocrine Surgery, University College London Hospitals, London, U.K.

Background/aim: Papillary thyroid cancer (PTC) is the most common endocrine malignancy with a rising incidence. There is a need for a non-invasive preoperative test to enable better patient counselling. The aim of this systematic review was to investigate the potential role of circulating microRNAs (miRNAs) in the diagnosis and prognosis of PTC. Read More

View Article and Full-Text PDF

Prediction of EVT6-NTRK3-Dependent Papillary Thyroid Cancer Using Minor Expression Profile.

Bull Exp Biol Med 2022 Jun 23. Epub 2022 Jun 23.

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.

Solid tumors resulting from oncogenic stimulation of neurotrophin receptors (TRK) by chimeric proteins are a group of rare tumors of various localization that respond to therapy with targeted drugs entrectinib and larotrectinib. The standard method for detecting chimeric TRK genes in tumor samples today is considered to be next generation sequencing with the determination of the prime structure of the chimeric transcripts. We hypothesized that expression of the chimeric tyrosine kinase proteins in tumors can determine the specific transcriptomic profile of tumor cells. Read More

View Article and Full-Text PDF

Coexistence of tuberculosis and extranodal marginal zone lymphoma of the thyroid gland: Case report and literature review.

Ann Med Surg (Lond) 2022 Jun 2;78:103861. Epub 2022 Jun 2.

Department of Surgery, Diyarbakir Education and Research Hospital, 21400, Diyarbakir, Turkey.

Introduction: Primary thyroid tuberculosis (TB) is rare even in countries where TB disease is endemic, with the prevalence ranging from 0.1 to 1.15%. Read More

View Article and Full-Text PDF

Analysis of Risk Factors Associated With Central Lymph Node Metastasis in Papillary Thyroid Carcinoma With cT1N0 Stage.

Front Endocrinol (Lausanne) 2022 3;13:880911. Epub 2022 Jun 3.

Department of Ultrasound Medicine, The First Affiliated Hospital of University of Science and Technology of China Anhui Provincial Hospital, Hefei, China.

Aim: Annual T1 stage papillary thyroid carcinoma (PTC) incidence rates continue to rise, yet the optimal treatment for this cancer type remains controversial. Central lymph node metastasis (CLNM) is a critical determinant in the context of treatment decision-making. While several prior studies have evaluated patients with clinica l T1a(cT1a) stage PTC, there have been fewer analyses of clinical T1b(cT1b) disease to date. Read More

View Article and Full-Text PDF

Endoscopic thyroidectomy via the combined trans-oral and chest approach for cT1-2N1bM0 papillary thyroid carcinoma.

Surg Endosc 2022 Jun 22. Epub 2022 Jun 22.

Department of Minimally Invasive Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of TCM), Guangzhou, 510120, People's Republic of China.

Background: Recent years there have been witnessed considerable advances in endoscopic selective lateral neck dissection (LND). However, dissection of lymph nodes at level IV and level VI via the chest approach is inherently challenging. In this study, we used combined trans-oral and chest approach for endoscopic thyroidectomy in patients with cT1-2N1bM0 papillary thyroid carcinoma (PTC). Read More

View Article and Full-Text PDF

Management dilemma in metastatic papillary thyroid carcinoma.

N Z Med J 2022 Jun 10;135(1556):127-131. Epub 2022 Jun 10.

Department of Otolaryngology-Head and Neck Surgery, Waikato Hospital, New Zealand.

Papillary thyroid cancer is the most common type of well-differentiated thyroid cancer. It is associated with a survival rate greater than 95% with appropriate treatment, particularly in younger patients. We present the unique case of a 25-year-old male with severe Autistic spectrum disorder (ASD) with a right level V neck mass of several months. Read More

View Article and Full-Text PDF

PDZK1 interacting protein 1 (PDZK1IP1) promotes the progression of papillary thyroid cancer.

J Clin Endocrinol Metab 2022 Jun 21. Epub 2022 Jun 21.

Department of Thyroid and Breast Surgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei Province 430030, China.

Background: The incidence of papillary thyroid cancer (PTC) has increased rapidly in recent decades, and tumor progression events are common in PTC. The purpose of our study is to identify the differentially expressed genes (DEGs) correlated with PTC progression and investigate the function of PDZK1IP1 in PTC.

Methods: We first analyzed DEGs associated with PTC progression between paired PTC and normal thyroid tissues in three GEO datasets (GSE29265, GSE33630 and GSE60542) and TCGA database. Read More

View Article and Full-Text PDF

Lenvatinib in multimodal therapy for unresectable radioactive iodine-naïve differentiated thyroid cancer: A case report with literature review.

Cancer Rep (Hoboken) 2022 Jun 17:e1654. Epub 2022 Jun 17.

Division of Medical Oncology, Department of Oncology, University of Western Ontario, London, Canada.

Background: Patients with unresectable or metastatic differentiated thyroid carcinoma (DTC) are rare and require individualized therapy. This may require approaches not typically used in resectable disease. We report a patient treated with lenvatinib and external beam radiation therapy. Read More

View Article and Full-Text PDF

Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma.

BMC Surg 2022 Jun 20;22(1):235. Epub 2022 Jun 20.

Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, 17th Tiyu Street, Wuhan, Hubei, 430060, The People's Republic of China.

Objective: It has been reported that papillary thyroid carcinoma (PTC) patients with lymph node metastasis (LNM) are largely associated with adverse outcomes. The present study aimed to assess the correlation between the number of metastatic lymph nodes (NMLNs) and clinical prognosis in patients with PTC.

Methods: We retrospectively reviewed the medical records of patients with PTC who underwent initial thyroid cancer surgery in Renmin Hospital of Wuhan University between 2017 and 2019. Read More

View Article and Full-Text PDF

Exposure to Polybrominated Diphenyl Ether Flame Retardants Causes Deoxyribonucleic Acid Damage in Human Thyroid Cells In Vitro.

J Surg Res 2022 Jun 17;279:77-83. Epub 2022 Jun 17.

Department of Surgery, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York. Electronic address:

Introduction: The incidence of papillary thyroid cancer (PTC) in the United States has tripled in the past 30 y. Polybrominated diphenyl ethers (PBDEs) are flame retardants that were ubiquitously used over that time period, and exposure to PBDEs has been associated with PTC prevalence. They are potential carcinogens via their induction of reactive oxygen species (ROS) formation and resultant deoxyribonucleic acid (DNA) damage. Read More

View Article and Full-Text PDF

Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing.

Endocr Relat Cancer 2022 Jun 1. Epub 2022 Jun 1.

E Morariu, Department of Medicine, University of Pittsburgh, Pittsburgh, United States.

The incidence of cancer in thyroid nodules carrying germline or somatic PTEN mutations is not well defined. This study characterizes clinical and histopathologic features of thyroid nodules with preoperatively detected PTEN mutations and their impact on management. Thyroid nodules with PTEN mutations on molecular testing of fine needle aspirate (FNA) specimens from November 2017 to July 2020 at our institution were included. Read More

View Article and Full-Text PDF

Propensity Score-Matched Analysis to Identify Pathways Associated with Loss of Sodium Iodide Symporter in Papillary Thyroid Cancer.

Curr Issues Mol Biol 2022 Mar 26;44(4):1488-1496. Epub 2022 Mar 26.

Department of Surgery, MacKay Memorial Hospital, Mackay Medical College, Taipei 104215, Taiwan.

Sodium iodide symporter (NIS) expression in thyroid follicular cells plays an important role in normal physiology and radioactive iodine therapy for thyroid cancer. Loss of NIS expression is often seen in thyroid cancers and may lead to radioiodine refractoriness. To explore novel mechanisms of NIS repression beyond oncogenic drivers, clinical and RNA-seq data from the thyroid cancer dataset of The Cancer Genome Atlas were analyzed. Read More

View Article and Full-Text PDF

Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy.

Front Endocrinol (Lausanne) 2022 26;13:870530. Epub 2022 May 26.

Department of Nuclear Medicine, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Context: Obesity has been reported as a potential risk factor for the aggressiveness of papillary thyroid cancer (PTC), but the data gathered so far are conflicting.

Objective: The aim of our study was to evaluate the relationship between body mass index (BMI) and aggressiveness of PTC at the diagnosis and clinical outcome.

Methods: A total of 337 patients who underwent radioactive iodine (RAI) therapy between March 2017 and May 2020 were recruited. Read More

View Article and Full-Text PDF

Extrathyroidal Extension Prediction of Papillary Thyroid Cancer With Computed Tomography Based Radiomics Nomogram: A Multicenter Study.

Front Endocrinol (Lausanne) 2022 1;13:874396. Epub 2022 Jun 1.

Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.

Objectives: To develop and validate a Computed Tomography (CT) based radiomics nomogram for preoperative predicting of extrathyroidal extension (ETE) in papillary thyroid cancer (PTC) patients.

Methods: A total of 153 patients were randomly assigned to training and internal test sets (7:3). 46 patients were recruited to serve as an external test set. Read More

View Article and Full-Text PDF

FTO Prevents Thyroid Cancer Progression by SLC7A11 m6A Methylation in a Ferroptosis-Dependent Manner.

Front Endocrinol (Lausanne) 2022 3;13:857765. Epub 2022 Jun 3.

Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

N6 methyladenosine (m6A) modification serves as a novel epigenetic regulatory mechanism that is heavily implicated in the heredity of tumors. Meanwhile, fat mass and obesity-associated protein (FTO) has the potential to affect the regulation of m6A modification in the mRNA of key oncogenes as well as tumor suppressor genes that facilitate tumor progression. In our study, FTO was downregulated in papillary thyroid carcinoma (PTC) tissues. Read More

View Article and Full-Text PDF

Clonal Distribution and Intratumor Heterogeneity of the TCR Repertoire in Papillary Thyroid Cancer With or Without Coexistent Hashimoto's Thyroiditis.

Front Immunol 2022 3;13:821601. Epub 2022 Jun 3.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Head & Neck Surgery, Peking University Cancer Hospital & Institute, Beijing, China.

The intratumor heterogeneity (ITH) of the amount and TCR repertoires of tumor infiltrating lymphocytes (TILs) in PTC with and without coexistent Hashimoto's thyroiditis (HT) are unclear. Here, we investigated the amount of T cells in tumor and corresponding normal tissues by immunohistochemical staining on 80 tumor samples and 40 normal samples from 40 patients. The immune repertoire of T cells was identified on 24 tumor samples and 12 normal samples from 12 patients using TCR high-throughput sequencing. Read More

View Article and Full-Text PDF

Analysis of the Clinical Value of Delphian Lymph Node Metastasis in Papillary Thyroid Carcinoma.

J Oncol 2022 10;2022:8108256. Epub 2022 Jun 10.

Department of Thyroid and Breast Surgery, The First People's Hospital of Yunnan Province, Kunming, China.

Purpose: Delphian lymph node (DLN) is often involved in metastasis of malignant head and neck tumors. This study evaluates the predictive utility of the DLN and the clinicopathological factors related to DLN metastasis in individuals suffering from papillary thyroid carcinoma (PTC). . Read More

View Article and Full-Text PDF

FOXP4-AS1 Inhibits Papillary Thyroid Carcinoma Proliferation and Migration Through the AKT Signaling Pathway.

Front Oncol 2022 2;12:900836. Epub 2022 Jun 2.

Clinical Medical College, Guizhou Medical University, Guiyang, China.

Papillary thyroid carcinoma, also known as PTC, is one of the commonest malignancies in the endocrine system. Long non-coding RNAs (lncRNAs) in PTC could maintain proliferative signaling, induce therapeutic resistance, activate invasion and migration, and sustain stem cell-like characteristics. In this paper, results showed that lncRNA forkhead box P4 antisense RNA 1 (FOXP4-AS1) is downregulated in PTC tissues and cell lines. Read More

View Article and Full-Text PDF